Sustained Engraftment and Tissue Enzyme Activity After Liver Cell Transplantation for Argininosuccinate Lyase Deficiency

Stéphenne, Xavier; Najimi, Mustapha; Sibille, Catherine; Nassogne, Marie‐Cécile; Smets, Françoise; Sokal, Étienne

doi:10.1053/j.gastro.2006.01.008

Cited by 193 publications

(139 citation statements)

References 32 publications

Supporting

Mentioning

138

Contrasting

Order By: Relevance

“…Hepatocyte isolation was performed by using two‐step collagenase perfusion under good manufacturing practice‐like conditions 22, 23, 24, 25. The isolated hepatocytes were stored in liquid nitrogen until use.…”

Section: Methodsmentioning

confidence: 99%

Age‐dependent glycosylation of the sodium taurocholate cotransporter polypeptide: From fetal to adult human livers

Sargiacomo

El-Kehdy

Pourcher

et al. 2018

Hepatology Communications

Self Cite

View full text Add to dashboard Cite

Sodium taurocholate cotransporter polypeptide (NTCP), mainly expressed on the sinusoidal membrane of hepatocytes, is one of the major transporters responsible for liver bile acid (BA) re‐uptake. NTCP transports conjugated BA from the blood into hepatocytes and is crucial for correct enterohepatic circulation. Studies have shown that insufficient hepatic clearance of BA correlates with elevated serum BA in infants younger than 1 year of age. In the current study, we investigated human NTCP messenger RNA and protein expression by using reverse‐transcription quantitative polymerase chain reaction and immunoblotting in isolated and cryopreserved human hepatocytes from two different age groups, below and above 1 year of age. Here, we show that NTCP messenger RNA expression is not modulated whereas NTCP protein posttranslational glycosylation is modulated in an age‐dependent manner. These results were confirmed by quantification analysis of NTCP 55‐kDa N‐glycosylated bands, which showed significantly less total NTCP protein in donors below 1 year of age compared to donors older than 1 year. NTCP tissue localization was also analyzed by means of immunofluorescence. This revealed that NTCP cellular localization in fetal samples was mainly perinuclear, suggesting that NTCP is not glycosylated, while its postnatal localization on the plasma membrane is age dependent compared to multidrug resistant protein 2, which is apical starting in fetal life. Conclusion: After birth, the NTCP age‐dependent maturation process requires approximately 1 year to complete NTCP glycosylation in human hepatocytes. Therefore, NTCP late posttranslational glycosylation appears to be important for correct NTCP membrane localization, which might explain physiologic cholestasis in neonatal life and might play a central role for HBV infection after birth. (Hepatology Communications 2018;2:693‐702)

show abstract

Section: Methodsmentioning

confidence: 99%

Age‐dependent glycosylation of the sodium taurocholate cotransporter polypeptide: From fetal to adult human livers

Sargiacomo

El-Kehdy

Pourcher

et al. 2018

Hepatology Communications

Self Cite

View full text Add to dashboard Cite

show abstract

“…Also, a temporary, but impressive, reduction in the requirement for exogenous recombinant factor VII was achieved by transplantation of adult hepatocytes to two children with inherited severe factor VII deficiency, although orthotopic liver transplants were required by both recipients after 6 months [46]. A better success was seen in a 3 year-old patient with a urea cycle disorder, arginosuccinate lyase deficiency, where a heroic course of 11 hepatocyte transplants achieved a peak of 19% donor hepatocytes at 8 months [47].…”

Section: Cell Therapies Using Hepatocytesmentioning

confidence: 99%

Stem cells in liver regeneration, fibrosis and cancer: the good, the bad and the ugly

Alison

Islam

Lim

2008

The Journal of Pathology

201

149

View full text Add to dashboard Cite

The worldwide shortage of donor livers to transplant end stage liver disease patients has prompted the search for alternative cell therapies for intractable liver diseases, such as acute liver failure, cirrhosis and hepatocellular carcinoma (HCC). Under normal circumstances the liver undergoes a low rate of hepatocyte 'wear and tear' renewal, but can mount a brisk regenerative response to the acute loss of two-thirds or more of the parenchymal mass. A body of evidence favours placement of a stem cell niche in the periportal regions, although the identity of such stem cells in rodents and man is far from clear. In animal models of liver disease, adopting strategies to provide a selective advantage for transplanted hepatocytes has proved highly effective in repopulating recipient livers, but the poor success of today's hepatocyte transplants can be attributed to the lack of a clinically applicable procedure to force a similar repopulation of the human liver. The activation of bipotential hepatic progenitor cells (HPCs) is clearly vital for survival in many cases of acute liver failure, and the signals that promote such reactions are being elucidated. Bone marrow cells (BMCs) make, at best, a trivial contribution to hepatocyte replacement after damage, but other BMCs contribute to the hepatic collagen-producing cell population, resulting in fibrotic disease; paradoxically, BMC transplantation may help alleviate established fibrotic disease. HCC may have its origins in either hepatocytes or HPCs, and HCCs, like other solid tumours appear to be sustained by a minority population of cancer stem cells.

show abstract

“…Recently, hepatocyte transplantation has been reported to improve metabolic abnormalities present in the animal models of Wilson's disease, Crigler-Nijjar syndrome type I, and hereditary tyrosinaemia type 1 and lowered serum cholesterol levels in a rabbit model of homozygous familial hyper-cholesterolemia (Overturf et al, 1996;Gunsalus et al, 1997;Park et al, 2006). Furthermore, promising results have been also demonstrated from hepatocyte transplantation in human diseases including glycogen storage disease type 1a, Crigler-Najjar syndrome type I, argininosuccinate lyase deficiency, and inherited factor VII deficiency (Fox et al, 1998;Muraca et al, 2002;Dhawan et al, 2004;Stephenne et al, 2006). However, only less than 100 hepatocyte transplantation cases have been reported in humans up to date.…”

Section: Introductionmentioning

confidence: 99%

Menstrual blood-derived mesenchymal stem cells differentiate into functional hepatocyte-like cells

Mou

Lin

Chen

et al. 2013

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Orthotopic liver transplantation (OLT) is the only proven effective treatment for both end-stage and metabolic liver diseases. Hepatocyte transplantation is a promising alternative for OLT, but the lack of available donor livers has hampered its clinical application. Hepatocyte-like cells (HLCs) differentiated from many multi-potential stem cells can help repair damaged liver tissue. Yet almost suitable cells currently identified for human use are difficult to harvest and involve invasive procedures. Recently, a novel mesenchymal stem cell derived from human menstrual blood (MenSC) has been discovered and obtained easily and repeatedly. In this study, we examined whether the MenSCs are able to differentiate into functional HLCs in vitro. After three weeks of incubation in hepatogenic differentiation medium containing hepatocyte growth factor (HGF), fibroblast growth factor-4 (FGF-4), and oncostain M (OSM), cuboidal HLCs were observed, and cells also expressed hepatocyte-specific marker genes including albumin (ALB), α-fetoprotein (AFP), cytokeratin 18/19 (CK18/19), and cytochrome P450 1A1/3A4 (CYP1A1/3A4). Differentiated cells further demonstrated in vitro mature hepatocyte functions such as urea synthesis, glycogen storage, and indocyanine green (ICG) uptake. After intrasplenic transplantation into mice with 2/3 partial hepatectomy, the MenSC-derived HLCs were detected in recipient livers and expressed human ALB protein. We also showed that MenSC-derived HLC transplantation could restore the serum ALB level and significantly suppressed transaminase activity of liver injury animals. In conclusion, MenSCs may serve as an ideal, easily accessible source of material for tissue engineering and cell therapy of liver tissues.

show abstract

Sustained Engraftment and Tissue Enzyme Activity After Liver Cell Transplantation for Argininosuccinate Lyase Deficiency

Cited by 193 publications

References 32 publications

Age‐dependent glycosylation of the sodium taurocholate cotransporter polypeptide: From fetal to adult human livers

Age‐dependent glycosylation of the sodium taurocholate cotransporter polypeptide: From fetal to adult human livers

Stem cells in liver regeneration, fibrosis and cancer: the good, the bad and the ugly

Menstrual blood-derived mesenchymal stem cells differentiate into functional hepatocyte-like cells

Contact Info

Product

Resources

About